HIGHBuilt-inProduct / Revenue mix
72%
Protein Sciences segment
“10-K Item 1: 'The Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2026.'”
TECH · Concentration risk · 10-K extracted
Bio-Techne (TECH) concentration risks
Updated
The most significant concentration Bio-Techne discloses is Protein Sciences segment at 72%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Bio-Techne’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
48%
sales outside the U.S.
“10-K Item 1A: 'approximately 48% of our sales revenue in fiscal 2026 coming from outside the U.S.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-10-18Bio-Techne's concentration is mainly one of mix. The Protein Sciences segment represented approximately 72% of net sales in fiscal 2026, a high-share exposure that is structural: it reflects the shape of the business rather than a dependency on any single customer or supplier. The company's fortunes therefore track the demand cycle, pricing and competitive position of that one segment more than anything else in the portfolio. The geographic exposure is smaller and more diffuse. Approximately 48% of sales revenue in fiscal 2026 came from outside the U.S., a medium-share exposure, also structural. It brings currency, regulatory and regional-demand sensitivity, but it is spread across many markets rather than tied to a named counterparty. Netting the two, the segment concentration is the one that could move the verdict, because a slowdown in that segment cannot be offset elsewhere in the company. The international share is more of a standing condition that adds variability around the edges. Neither source points to an idiosyncratic single-name risk, and both are clearly disclosed in the filing.
For the engine’s reasoning on TECH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| TECH● | Bio-Techne Corp | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.